<SEC-DOCUMENT>0001140361-16-066956.txt : 20160624
<SEC-HEADER>0001140361-16-066956.hdr.sgml : 20160624
<ACCEPTANCE-DATETIME>20160525070302
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-16-066956
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Summit Financial Printing, LLC
    Document created using EDGARfilings PROfile 4.0.1.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BACKGROUND-COLOR: #000000; COLOR: #000000; HEIGHT: 4px; MARGIN-LEFT: auto; MARGIN-RIGHT: auto; text-align: center; TEXT-ALIGN: center" noshade="noshade">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z878eb63e9e644257bd5fefee8b55855a" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="TEXT-ALIGN: left; WIDTH: 60%; VERTICAL-ALIGN: middle"><img src="logo1.jpg"></td>
<td style="WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DLA Piper LLP (US)</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4365 Executive Drive, Suite 1100</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">San Diego, California 92121-2133</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">www.dlapiper.com</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Jeffrey T. Baglio</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Jeff.baglio@dlapiper.com</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">T</font> 858.677.1458</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">F</font> 858.638.5058</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">May 25, 2016</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Via UPS</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Amanda Ravitz</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Assistant Director</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Securities and Exchange Commission</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Division of Corporation Finance</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">100 F Street, NE</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Washington, DC 20549</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z15e2aeac7e9047bf84135ea0b81a9723" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Re:</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Cytori Therapeutics, Inc.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amendment No. 1 to Registration Statement on Form S-1</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Filed May 10, 2016</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">File No. 333-210628</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ladies and Gentlemen:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This letter responds to the letter of the staff (the &#8220;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><u>Staff</u></font>&#8221;) of the United States Securities and Exchange Commission, dated May 24, 2016, to Marc H. Hedrick, MD, President and Chief Executive Officer of Cytori Therapeutics, Inc. (the &#8220;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><u>Company</u></font>&#8221;) regarding the Amendment No. 1 to Registration Statement on Form S-1 filed by the Company on May 10, 2016 (the &#8220;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><u>Registration Statement</u></font>&#8221;). The Company is publicly filing under separate cover Amendment No. 2 to the Registration Statement (the &#8220;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><u>Amendment</u></font>&#8221;) in response to the Staff&#8217;s comments.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This letter sets forth the comment of the Staff in the comment letter and, following the comment, sets forth the Company&#8217;s response. We are enclosing a copy of the Amendment, together with a copy that is marked to show the changes from the initial filing.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Use of Proceeds</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za62e1edb058b4e19aefb19115f1d68ba" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-STYLE: italic; WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">1.</td>
<td style="TEXT-ALIGN: left; FONT-STYLE: italic; WIDTH: auto; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">We note your response to prior comment 3. If material amounts of other funds are necessary to accomplish the purposes for which the proceeds are to be obtained, state the amounts and intended sources of such funds needed for each specified purpose and the sources thereof.</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Response:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In response to the Staff&#8217;s comment, and as discussed with Staff, the Company has revised the referenced disclosure (1) to clarify the primary uses of proceeds and the order of any residual uses, and (2) to state that the Company believes, even if it were only able to sell 25% of the maximum amount of units, that the net proceeds from the rights offering together with its cash on hand will be sufficient to fund its primary uses of proceeds.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Exhibit 5.1</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc1bf6fb721184bc8939e7d19e1c44074" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-STYLE: italic; WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">2.</td>
<td style="TEXT-ALIGN: left; FONT-STYLE: italic; WIDTH: auto; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Please revise to opine that the rights and warrants are binding obligations of the registrant under the law of the jurisdiction governing those securities. Please refer to Section II.B.1.f. of Staff Legal Bulletin No. 19 available on our website.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div>&#160;</div>

<div><img src="logo1.jpg"></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">May 25, 2016</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Page Two</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Response:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In response to the Staff&#8217;s comment, the Company has filed with the Amendment a revised Exhibit 5.1 opinion, which opines that the rights and warrants are binding obligations of the registrant under the law of the jurisdiction governing those securities.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We and the Company very much appreciate the Staff&#8217;s attention to the review of the Registration Statement. Please do not hesitate to contact me at (858) 677-1458 if you have any questions regarding this letter, the Registration Statement or the Amendment.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Very truly yours,</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DLA Piper LLP (US)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">/s/ Jeffrey Baglio</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Jeffrey Baglio</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Partner</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cc: Via E-mail</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Securities and Exchange Commission:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">Tim Buchmiller</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">Tom Jones</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Cytori Therapeutics, Inc.:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">Marc H. Hedrick, MD</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">DLA Piper LLP (US):</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">Andrew Ledbetter</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">Patrick O&#8217;Malley</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 72pt; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<hr style="BACKGROUND-COLOR: #000000; COLOR: #000000; HEIGHT: 2px; MARGIN-LEFT: auto; MARGIN-RIGHT: auto; text-align: center; TEXT-ALIGN: center" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) 'L# 2(  A$! Q$!_\0
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M\X0_#37Y'E97FW%F95?8X'$5ZDO*I-V]7>R^94_X?+_M)_\ 11__ "W]+_\
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M6RN[[3[**6)3&[*7.'^4'8Q&[' [5^#9;DV-S!R6#IN7+:^VE]M['])9KGV
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MG)*G""O[RLWRW>YY>0<,YSDV+CB*=.%12ARR]]Q46ZLYOE]QW24K+:]CX_\
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H9X^NJT[_ !*"AIVLFU\_P"BBBO//4"BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
